LYKA LABS
|
|
BOM : 500259     NSE : LYKALABS     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Mild Upward Pledged Shares : NA |
Jan 27,2023 |
Price(EOD): βΉ 131.15
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: βΉ 376.40 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
LYKA LABS | -11.5% | 1.5% | -36.1% |
SUN PHARMACEUTICAL INDUSTRIES | 1.3% | 4.9% | 30% |
DIVIS LABORATORIES | 1.3% | -1.7% | -17.5% |
CIPLA | -0.6% | -3.5% | 16% |
DR REDDYS LABORATORIES | -0.8% | 1.5% | -3.6% |
TORRENT PHARMACEUTICALS | -2.8% | -2.4% | 0.3% |
ABBOTT INDIA | -2.4% | -2% | 30.2% |
ZYDUS LIFESCIENCES | -1.7% | 3.7% | 7.4% |
ALKEM LABORATORIES | -1.1% | -0.9% | -13.9% |
FUNDAMENTAL ANALYSIS OF LYKA LABS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF LYKA LABS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
-45.08
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -8.35 Cr
[Latest Qtr - Sep2022 - Consolidated Results ] 28.21
P/B Calculated based on Book Value of Rs 13.34 Cr
[Latest Year - Mar2022 - Consolidated Results ] 3.04
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 123.78 Cr
[Latest Qtr - Sep2022 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-23% 228% 423% |
SHARE PRICE MOMENTUM OF LYKA LABS
LYKA LABS vs SENSEX
DEBT OF LYKA LABS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
2.9 36.68 7.29 15.62 |
9.76 -6.3 -9.85 -2.13 |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF LYKA LABS
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF LYKA LABS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-7.15% -20.2% -184.36% -148.31% |
-65.45% -88.98% -101.93% -101.24% |
QtrlyTrend |
-8 | |
Latest Qtr: Sep2022 | ||
Quarterly Result Analysis → |
LYKA LABS related INDICES
You may also like the below Video Courses
FAQ about LYKA LABS
Is LYKA LABS good for long term investment?
As on Jan 27,2023, the Fundamentals of LYKA LABS look Poor and hence it may not be good for long term investment ! See Financial Performance of LYKA LABS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is LYKA LABS UnderValued or OverValued?
As on Jan 27,2023, LYKA LABS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of LYKA LABS ?
As on Jan 27,2023, the Intrinsic Value of LYKA LABS is Rs. 39.98 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 171.40
Fair Value [Median EV / Sales Model] : Rs. 39.98
Fair Value [Median Price / Sales Model] : Rs. 25.10
Estimated Median Fair Value of LYKA LABS : Rs. 39.98
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is LYKA LABS trading at a Premium or Discount?
As on Jan 27,2023, LYKA LABS is trading at a Premium of 228% based on the estimates of Median Intrinsic Value!